GlassScriptPhysician profile
Melody Recio
NPI 1518520311
$1,945.78
in general payments reported to CMS, 2019-2025
20 companies · $1,583 in 2025
The $1,583 reported for 2025 was more than what 98% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $72.36 · 2024: $290 · 2025: $1,583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,945.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $536.25 | 2025 | Tavneos, Krystexxa, Uplizna |
| Abbvie INC. | $240.89 | 2025 | |
| Lilly USA, LLC | $176.39 | 2025 | Zepbound, Taltz |
| Merck Sharp & Dohme LLC | $143.39 | 2023-2025 | M-M-R II, Gardasil 9, Vaxelis |
| Recordati_rare_diseases_inc. | $132.89 | 2025 | Isturisa |
| Glaxosmithkline, LLC. | $125.00 | 2024 | Bexsero |
| Cranial Technologies, INC | $99.61 | 2024-2025 | Doc Band |
| Janssen Biotech, INC. | $82.44 | 2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $82.41 | 2025 | |
| Verrica Pharmaceuticals INC. | $56.52 | 2024-2025 | Ycanth |
| Ucb, INC. | $54.82 | 2025 | Bimzelx |
| Ani Pharmaceuticals, INC. | $44.10 | 2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $29.68 | 2025 | Acthar |
| Tonix Medicines, INC. | $27.10 | 2025 | Tonmya |
| Astrazeneca Pharmaceuticals LP | $22.59 | 2025 | Saphnelo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $20.89 | 2025 | Ultomiris |
| Aurinia Pharma U.S., INC. | $20.89 | 2025 | Lupkynis |
| Genentech USA, INC. | $19.08 | 2025 | Gazyva |
| Fresenius Kabi USA, LLC | $16.69 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $14.15 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melody Recio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.